Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - losartan potassium - film-coated tablet - losartan potassium 50 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - losartan potassium - film-coated tablet - losartan potassium 100 mg - agents acting on the renin-angiotensin system

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - losartan potassium - film-coated tablet - 100 milligram(s) - angiotensin ii antagonists, plain; losartan

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - losartan potassium - film-coated tablet - 25 milligram(s) - angiotensin ii antagonists, plain; losartan

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - losartan potassium - film-coated tablet - 50 milligram(s) - angiotensin ii antagonists, plain; losartan

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - losartan potassium - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - losartan potassium - oral tablet - 100mg

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - losartan potassium - film coated tablets - losartan potassium 12.5 mg - losartan - losartan - heart failure: losartan 12.5 mg is indicated for the treatment of heart failure, when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to losartan 12.5 mg is not recommended

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - losartan potassium - film coated tablets - losartan potassium 50 mg - losartan - losartan - hypertension: losartan 50 mg is indicated for the treatment of hypertensionheart failure: losartan 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to losartan 50 mg is not recommended.renal protection in type-2 diabetic patients with proteinuria: losartan 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losartanmg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with

United States - English - NLM (National Library of Medicine)

sandoz inc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 50 mg - losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, f